Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2014

View Archived Issues

One Lambda licenses HLA primer technology from GenoDive Pharma

NIAID grant supports TB drug development at Microbiotix

Yabao and Lilly partner on glucokinase activator in China

Once-daily tofacitinib shows bioequivalence for the immediate-release formulation

Mariel Therapeutics to acquire Stryker's BMP-7 assets

Arrien Pharmaceuticals prepares new SIK-2 inhibitors

Researchers at AbbVie synthesize novel PKC inhibitors for autoimmune diseases

New orexin receptor antagonists reported by Taisho Pharmaceutical

Takeda Pharmaceutical synthesizes new CH24H inhibitors

Enrollment begins in phase I trial of TPI-287 in rare tauopathy diseases

Genmab achieves third milestone in daratumumab collaboration

Novel lipidated NMU analogues with promise for suppressing food intake in vivo

Cellceutix patents novel agents for bacterial and other infections

Patient enrollment completed in phase II trial of carboplatin, paclitaxel and Reolysin

Biotie awarded Michael J. Fox Foundation grant for a clinical study of SYN-120

Merck & Co. discloses new BACE inhibitors for Alzheimer's disease

Portola Pharmaceuticals and Daiichi Sankyo form second collaboration

Eagle Pharmaceuticals' bendamustine hydrochloride product receives orphan drug status

Avraham Pharmaceuticals reports interim data from phase IIb study of ladostigil

Cesca Therapeutics discusses pivotal trial for CLIRST with FDA

FDA approves Kerydin for onychomycosis

Promising phase II and III results for a number of novel oncolytics presented at ASCO

Japanese approval of Jakavi triggers milestone payment to Incyte

InSite Vision plans NDA filing for DexaSite next year

CardioCell initiates phase II trial of allogeneic stem cell therapy for chronic heart failure

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...